88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 383
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Brian M. Goff M.B.A. | CEO & Director | 1,46M | S.O. | 1969 |
Ms. Cecilia Jones | Chief Financial Officer | 751,48k | S.O. | 1975 |
Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 1,02M | S.O. | 1978 |
Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 1,25M | S.O. | 1980 |
Ms. Tsveta Milanova | Chief Commercial Officer | 939,05k | S.O. | 1977 |
Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | S.O. | 1949 |
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | 1946 |
Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | S.O. | S.O. | 1953 |
Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | 1956 |
Mr. T. J. Washburn | Principal Accounting Officer | S.O. | S.O. | 1982 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
L’ISS Governance QualityScore de Agios Pharmaceuticals, Inc. en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 7; Compensation : 6.